The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Please provide your email address to receive an email when new articles are posted on . Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients ...

Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...

The maintenance inhalers available for obstructive lung disease are long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs). We use all three ...

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis. Our ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...

LAMAs were found to be safe and effective in the treatment of COPD and have been recommended by international clinical guidelines for the management of symptoms in COPD. A population-based cohort ...

Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...